Bupropion as a modulator of drug activity
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1. A method of treating major depressive disorder, comprising orally administering a dosage form once a day or twice a day to a human patient in need thereof, wherein the dosage form contains about 40 mg to about 50 mg of a dextromethorphan salt, or a molar equivalent amount of the free base form of dextromethorphan, and about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form or the free base form of bupropion.
2. The method of claim 1 , wherein the dosage form contains about 45 mg of the dextromethorphan salt.
3. The method of claim 1 , wherein the dosage form is orally administered once a day for three days, and after three days, the dosage form is orally administered twice a day.
4. The method of claim 1 , wherein the dosage form contains about 105 mg of bupropion hydrochloride.
5. The method of claim 4 , wherein the dosage form contains about 45 mg of the dextromethorphan salt.
6. The method of claim 5 , wherein the dosage form is orally administered once a day for three days, and after three days, the dosage form is orally administered twice a day.
7. The method of claim 6 , wherein the dosage form provides sustained release of bupropion and immediate release of dextromethorphan.
8. The method of claim 7 , wherein the dosage form is in the form of a tablet.
9. The method of claim 8 , wherein the tablet further contains magnesium stearate.
10. The method of claim 9 , wherein the tablet further contains microcrystalline cellulose.
11. The method of claim 1 , wherein the dextromethorphan salt is dextromethorphan hydrobromide.
12. The method of claim 11 , wherein the dosage form contains about 45 mg of dextromethorphan hydrobromide.
13. The method of claim 12 , wherein the dosage form contains about 105 mg of bupropion hydrochloride.
14. The method of claim 13 , wherein the dosage form is orally administered once a day for three days, and after three days, the dosage form is orally administered twice a day.
15. The method of claim 14 , wherein the dosage form provides sustained release of bupropion and immediate release of dextromethorphan.
16. The method of claim 15 , wherein the dosage form is in the form of a tablet.
17. The method of claim 16 , wherein the tablet further contains magnesium stearate.
18. The method of claim 17 , wherein the tablet further contains microcrystalline cellulose.